Opyl (ASX:OPL) - Chief Executive Officer, Michelle Gallaher (Middle) Head of Services at Opyl, Dr Nicola Straiton (Left) and Mexec founder, Marilyn Jones (Right)
Chief Executive Officer, Michelle Gallaher (Middle) Head of Services at Opyl, Dr Nicola Straiton (Left) and Mexec founder, Marilyn Jones (Right)
Source: Marilyn Jones/Twitter
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Opyl (OPL) enters into a master services agreement (MSA) and agrees to recruitment contracts worth $145,000 with Bristol Myers Squibb (BMS)
  • The contracts will benefit clinical studies in psoriatic arthritis through the use of the company’s innovative Opin.AI platform
  • With 80 per cent of trials across the globe failing to recruit on time or on budget, Opyl’s platform limits the risk of clinical trial failures
  • MSA places Opyl as approved and preferred supplier to BMS, helping to secure other contracts and further push revenue growth
  • OPL shares are up 31 per cent, trading at 3.8 cents at 1:57 pm AEDT

Opyl (OPL) has entered into a master services agreement (MSA) and signed contracts to offer clinical trial recruitment services worth $145,000 to Bristol Myers Squibb (BMS).

BMS is a leading global pharmaceutical company, developing innovative medicines to help patients overcome serious diseases.

The recruitment contracts will benefit clinical studies in psoriatic arthritis, which involves 120 patients and is carried out over six months, commencing immediately.

Bristol Myers Squibb chose Opyl’s innovative Opin.AI platform, a digital health research recruitment solution, as it has a proven track record of swift and accurate participant recruitment.

With 80 per cent of trials across the globe failing to recruit on time or on budget, Opyl’s platform mitigates risks associated with clinical trial failures.

The revenue from the contracts, along with the MSA, will boost Opyl’s status as approved and preferred supplier status, allowing the company to bid and secure additional or local contracts with BMS.

“MSAs provide us a clear pathway to grow Opin.AI’s revenue exponentially,” Opyl Chief Executive Officer Michelle Gallaher said.

“The outlook for Opyl is particularly bright given that we have also recently signed an MSA with British pharmaceutical giant GSK plc and are working actively with them on securing recruitment contracts.”

With more than 50 compounds in development in more than 35 diseases area globally, Opyl believes it can assist BMS in de-risking its clinical development programs.

OPL shares were up 31 per cent, trading at 3.8 cents at 1:57 pm AEDT.

OPL by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Consumer Discretionary rises ahead of interest rates decision | June 14, 2024

The ASX200 is down a third of a per cent to close the week. All sectors…
The Market Online Video

ASX Market Update: ASX slips 0.3%, Discretionary is the only sector to rise | 14 June, 2024

The ASX200 is trading down around 0.3%. The discretionary sector has made gains of 0.3%, all…

Week 24 Wrap: US contagion sentiment not so contagious; iron ore remains pressured

It was, overall, a lacklustre week for the ASX. We only saw one green day on…
The Market Online Video

Geology is King: Sun Silver says Maverick Springs will outshine high-grade Australian mines

Sun Silver Ltd (ASX:SS1) is seeking gold, silver and pathfinder elements at their Maverick Springs project…